Conducting R&D activities generates new knowledge that can benefit the nation’s economy. In a recent AusIndustry information bulletin, it was mentioned that one of the main aims of the R&D Tax Incentive is to encourage Australian businesses to undertake research and development that would not be conducted otherwise. This is achieved by helping to offset some of the costs of engaging in R&D. Useful information on the R&D Tax Incentive can be accessed from page 24 in the Innovation and […]
StartupAUS, Australia’s national startup advocacy group has released a report titled Crossroads – Fifth Anniversary edition. Data from the company has found that almost 90 percent of startups rate the R&D tax incentive as “very important” or “critical” to their business’s success. Within the report, they have called for greater assurance for software companies accessing the R&D Tax Incentive, and put forward proposals including: A moratorium on audits for software claims; A legislative amendment to the R&D Tax Incentive, or […]
Reports have emerged in the media recently of software development companies that have been subject to adverse R&D Tax Compliance proceedings. Whilst the benefits available under the R&D Tax Incentive are significant, these reports affirm the need to ensure R&D claims are completed with diligence, and in accordance with the current reporting expectations. Recent publications from ATO and AusIndustry on software development activities have highlighted current regulatory compliance focuses, which include the need to: Detail the specific hypothesis, or central […]
Despite Switzerland being known as one of the most innovative nations, latest reports have shown a 10% decline in the country’s research and development spending. This comes as a surprise due to the fact that worldwide R&D expenditure has reached an all-time high of $782 billion. The biggest Swiss companies invested $27.5 billion into R&D in 2018. The majority of the decline has come from Basel-based giant pharmaceutical companies Roche and Novartis. Roche spent around $1 billion less on R&D […]